← Back to headlines
Novo Nordisk Shares Plunge After Obesity Drug Fails to Outperform Zepbound
Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.
23 Feb, 16:44 — 23 Feb, 16:44
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippines Energy Secretary Confirms Diesel Cargo Arrival Amid Petronas Denial
just now
Philippine President Marcos Urges Unity, Warns Against Hoarding Amid Energy Crisis
just now
Marcos to decide on fuel excise tax cut or suspension by April 13
just now